Búsqueda in silico de inhibidores de la enzima Tripanotión reductasa de Leishmania (Viannia) panamensis

Abstract

Health problem that affects all low-income populations in underdeveloped and developing countries, from 2003, Colombia has experienced Important number of cases, due to the appearance of new outbreaks, which has modified the epidemiological pattern and suggests a movement of the disease from the rural areas to the urban area putting at risk about 11 million inhabitants, the most Worrying is that this is a disease considered as neglected according to the Panamerican Health Organization which involves a lot of challenges and obstacles like; High incidence, high morbidity, wide geographic distribution, variety of parasite species and clinical forms, lack of therapeutic schemes and adequate prevention measures. Undoubtedly one of the greatest challenges to overcome is related to pharmacological treatments, since the number of drugs currently available in our country is limited (pentavalent antimonials, pentamidine, amphotericin B, miltefosine, ketoconazole). Adverse effects related to toxicity, resistance by strains of the parasite, long duration of treatments, patient relapse and high cost in countries where leishmaniasis is endemic.